


Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

## **Complete if Known**

Application Number	10/827,024
Filing Date	April 19, 2004
First Named Inventor	Kwok et al.
Group Art Unit	1615
Examiner Name	Unassigned
Attorney Docket Number	217538

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date if Appropriate
		Application or Patent Number	Kind Code			
CK	AA	4,885,275		Robison	Dec. 5, 1989	
	AB	5,360,593	A	Bapatia	Nov. 1, 1994	
	AC	6,670,384	B2	Bandyopadhyay et al.	Dec. 30, 2003	
	AD	2002/0164372	A1	Pestka	Nov. 7, 2002	
CK	AE	2003/0017169	A1	Pestka	Jan. 23, 2003	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
CK	AF	WO	02/053174	A2	PBL Biomedical Laboratories	Jul. 11, 2002		
CK	AG	WO	02/058700	A1	Bristol-Myers Squibb Company	Aug. 1, 2002		
CK	AH	WO	02/062338	A1	Bristol-Myers Squibb Company	Aug. 15, 2002		

## **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
CK	AI	WITTAYA-AREEKUL et al., <i>Journal of Pharmaceutical Sciences</i> , 91 (4), 1147-1155 (2002)		

Examiner Signature

G. Krizian

Date Considered

1/5/07

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).